Incyte, an American multinational pharmaceutical company, completed the acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company, for $750m. "The acquisition of Escient and its first-in-class oral MRGPR antagonists bolsters our Inflammation and Autoimmunity portfolio and our commitment to creating innovative solutions that address the urgent needs of patients living with severe inflammatory diseases. We are excited to continue the work started by the Escient team and accelerate the clinical development of these promising therapies,” Hervé Hoppenot, Incyte CEO.